Prolonged tedizolid use in cutaneous non-tuberculous mycobacterial infection

Timothy David Shaw, Mark Smyth, Graham Turner, Michael Hunter

Research output: Contribution to journalArticlepeer-review

24 Downloads (Pure)


Cutaneous non-tuberculous mycobacterial (NTM) infections are an emerging infectious disease and require a protracted course of combination antibiotics. Antimicrobial choice is limited by resistance and toxicity. Tedizolid is a new oxazolidinone antibiotic with activity against some NTM, but its use in the management of extrapulmonary NTM has not been described. We report on the utility of prolonged tedizolid use (8 months), after linezolid intolerance, in combination therapy in a case of difficult cutaneous infection. Although tedizolid contributed to clinical remission, it may have also contributed to a multifocal peripheral neuropathy. Its efficacy may also have been limited by continued immunosuppression, with evidence to suggest disease relapse or treatment failure after completion of combination therapy. Tedizolid can be considered, with caution, in combination therapy for difficult cases of cutaneous NTM infection.
Original languageEnglish
Article number100261
JournalJournal of clinical tuberculosis and other mycobacterial diseases
Early online date14 Jul 2021
Publication statusPublished - Aug 2021


  • Non-tuberculous mycobacteria
  • Extrapulmonary infection
  • Tedizolid
  • Mycobacterium chelonae


Dive into the research topics of 'Prolonged tedizolid use in cutaneous non-tuberculous mycobacterial infection'. Together they form a unique fingerprint.

Cite this